Third Rock-launched Pliant is latest biotech to climb on public debut

Three more biotechs hope to price deals on NASDAQ this week

Pliant joins a slew of recent biotechs that have seen substantial first-day gains.

The fibrosis company closed up $5.30 (33%) to $21.30 on Wednesday after raising $144 million through the sale of

Read the full 329 word article

How to gain access

Continue reading with a
two-week free trial.